Øyvind Molberg

Øyvind Molberg is a Professor at the Department of Rheumatology and Infectious Diseases, Faculty of Medicine, University of Oslo. His clinical and research work is closely affiliated with Oslo University Hospital (OUS Rikshospitalet), where he maintains a visiting address at Sognsvannsveien 20, 0372 Oslo. Molberg's research focuses on autoimmune diseases with particular emphasis on systemic sclerosis, systemic lupus erythematosus, vasculitis, and related conditions.

His research interests span multiple dimensions of rheumatic diseases. Molberg investigates genetic factors underlying autoimmune conditions, particularly HLA associations and genetic architecture of inflammatory myopathies. He has significant expertise in interstitial lung disease associated with systemic sclerosis, developing and validating diagnostic methods using HRCT scans. His work also explores gastrointestinal manifestations in rheumatic diseases, including studies on faecal microbiota transplantation for systemic sclerosis patients. Molberg contributes substantially to epidemiological research on autoimmune diseases, examining incidence, prevalence, and mortality patterns in Norwegian populations.

Molberg's recent publications reveal evolving research trends toward understanding the genetic basis of autoimmune diseases and developing improved diagnostic criteria. His work increasingly integrates multi-omics approaches to identify biomarkers and therapeutic targets. The research demonstrates strong clinical translation, with studies on vascular ultrasound for giant cell arteritis monitoring and validation of diagnostic criteria for IgG4-related disease. His contributions to understanding disease progression in systemic sclerosis and lupus highlight his focus on improving patient outcomes through better diagnostics and monitoring strategies.

Molberg actively collaborates with numerous researchers across Norway and internationally, as evidenced by his extensive co-authorship on multi-center studies. His work frequently appears in high-impact rheumatology journals including Arthritis & Rheumatology, The Lancet Rheumatology, and RMD Open. While specific grant information isn't detailed in the provided text, his leadership in clinical trials like the ReSScue study on faecal microbiota transplantation suggests substantial research funding support.